COPILOT-HF: Cooperative Program for ImpLementation of Optimal Therapy in Heart Failure

Completed · Phase 4

Conditions studied: Heart Failure

In brief

This is a randomized, open-label, initiative within the Mass General Brigham healthcare system testing two remote care strategies for optimizing the prescription of guideline-directed medical therapies in patients with heart failure, regardless of left ventricular ejection fraction (LVEF).

Key facts

Study ID: NCT05734690
Run by: Brigham and Women's Hospital
People needed: 503
Starts: 2023-05-05
Expected to finish: 2025-06-09
Last updated by the study team: 2026-02-06

Who can join

Age: 18 and older, up to 90. Sex: any. Healthy volunteers: accepted.

You may qualify if…

Documented diagnosis of heart failure (e.g., ICD-9 codes 428 ICD-10 codes I50 or Problem list in the electronic health record)
Most recent EF assessed within the past 24 months
Seen Mass General Brigham provider within the last 24 months
English or Spanish speaking

You may not qualify if…

LVEF<50% currently prescribed or intolerant to both ARNi and SGLT2i
LVEF>50% currently prescribed or intolerant to SGLT2i
Systolic blood pressure (SBP) <90 mmHg at last measure
Current severe aortic stenosis or severe aortic insufficiency
Known amyloid heart disease
Group 1 pulmonary arterial hypertension on disease-specific therapies (e.g., Ambrisentan, Bosentan, Epoprostenol, Treprostinil, Iloprost)
eGFR<30 mL/min/1.73m2
Active chemotherapy
Receiving end-of-life care or hospice
History of transplant, currently listed above status 4 or being evaluated for transplant
Outpatient intravenous inotrope use
Current use of a Ventricular Assist Device
Physician's discretion as inappropriate for remote management program

Where it is running

Brigham and Women's Hospital — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.